Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy

Mathilde Skaarup Larsen, Karsten Bjerre, Anne Elisabeth Lykkesfeldt, Anita Giobbie-Hurder, Anne Vibeke Lænkholm, Katrine L Henriksen, Bent Laursen Ejlertsen, Birgitte Rasmussen

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

The four human epidermal growth factor receptors (HER1-4) are involved in growth stimulation and may play a role in endocrine resistance. The receptors form dimers, leading to activation by mutual phosphorylation. Our purpose was to explore the role of the activated receptors (pHER1, pHER2, pHER3) in endocrine treated breast cancer in terms of co-expression and association with disease-free survival (DFS) in 1062 patients with ER-positive tumors. Furthermore, HER2 amplification was evaluated. We found positive associations between the phosphorylated receptors. pHER1 and pHER3 were co-expressed with one or two of the other activated receptors in 85% and 89% of tumors, respectively, whereas pHER2 was co-expressed with the other activated receptors in 54% of tumors. Except for HER2, which was associated with poor prognosis, none of the remaining markers were associated with DFS. However, frequent co-expression indicates a role of the other HER-family members in activation of HER2.
OriginalsprogEngelsk
TidsskriftBreast
Vol/bind21
Udgave nummer5
Sider (fra-til)662-8
Antal sider7
ISSN0960-9776
DOI
StatusUdgivet - 2012

Fingeraftryk

Disease-Free Survival
Neoplasms
Growth

Citer dette

Larsen, M. S., Bjerre, K., Lykkesfeldt, A. E., Giobbie-Hurder, A., Lænkholm, A. V., Henriksen, K. L., ... Rasmussen, B. (2012). Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy. Breast, 21(5), 662-8. https://doi.org/10.1016/j.breast.2012.07.005
Larsen, Mathilde Skaarup ; Bjerre, Karsten ; Lykkesfeldt, Anne Elisabeth ; Giobbie-Hurder, Anita ; Lænkholm, Anne Vibeke ; Henriksen, Katrine L ; Ejlertsen, Bent Laursen ; Rasmussen, Birgitte. / Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy. I: Breast. 2012 ; Bind 21, Nr. 5. s. 662-8.
@article{d7f3dab49a084c0f94adfa76053fb30a,
title = "Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy",
abstract = "The four human epidermal growth factor receptors (HER1-4) are involved in growth stimulation and may play a role in endocrine resistance. The receptors form dimers, leading to activation by mutual phosphorylation. Our purpose was to explore the role of the activated receptors (pHER1, pHER2, pHER3) in endocrine treated breast cancer in terms of co-expression and association with disease-free survival (DFS) in 1062 patients with ER-positive tumors. Furthermore, HER2 amplification was evaluated. We found positive associations between the phosphorylated receptors. pHER1 and pHER3 were co-expressed with one or two of the other activated receptors in 85{\%} and 89{\%} of tumors, respectively, whereas pHER2 was co-expressed with the other activated receptors in 54{\%} of tumors. Except for HER2, which was associated with poor prognosis, none of the remaining markers were associated with DFS. However, frequent co-expression indicates a role of the other HER-family members in activation of HER2.",
keywords = "Aged, Antineoplastic Agents, Hormonal, Breast Neoplasms, Chemotherapy, Adjuvant, Disease-Free Survival, Double-Blind Method, Female, Follow-Up Studies, Humans, Immunohistochemistry, In Situ Hybridization, Fluorescence, Mastectomy, Middle Aged, Nitriles, Phosphorylation, Receptor Protein-Tyrosine Kinases, Receptor, Epidermal Growth Factor, Receptor, erbB-2, Receptor, erbB-3, Tamoxifen, Treatment Outcome, Triazoles, Tumor Markers, Biological",
author = "Larsen, {Mathilde Skaarup} and Karsten Bjerre and Lykkesfeldt, {Anne Elisabeth} and Anita Giobbie-Hurder and L{\ae}nkholm, {Anne Vibeke} and Henriksen, {Katrine L} and Ejlertsen, {Bent Laursen} and Birgitte Rasmussen",
note = "Copyright {\circledC} 2012 Elsevier Ltd. All rights reserved.",
year = "2012",
doi = "10.1016/j.breast.2012.07.005",
language = "English",
volume = "21",
pages = "662--8",
journal = "Breast",
issn = "0960-9776",
publisher = "Churchill Livingstone",
number = "5",

}

Larsen, MS, Bjerre, K, Lykkesfeldt, AE, Giobbie-Hurder, A, Lænkholm, AV, Henriksen, KL, Ejlertsen, BL & Rasmussen, B 2012, 'Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy', Breast, bind 21, nr. 5, s. 662-8. https://doi.org/10.1016/j.breast.2012.07.005

Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy. / Larsen, Mathilde Skaarup; Bjerre, Karsten; Lykkesfeldt, Anne Elisabeth; Giobbie-Hurder, Anita; Lænkholm, Anne Vibeke; Henriksen, Katrine L; Ejlertsen, Bent Laursen; Rasmussen, Birgitte.

I: Breast, Bind 21, Nr. 5, 2012, s. 662-8.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy

AU - Larsen, Mathilde Skaarup

AU - Bjerre, Karsten

AU - Lykkesfeldt, Anne Elisabeth

AU - Giobbie-Hurder, Anita

AU - Lænkholm, Anne Vibeke

AU - Henriksen, Katrine L

AU - Ejlertsen, Bent Laursen

AU - Rasmussen, Birgitte

N1 - Copyright © 2012 Elsevier Ltd. All rights reserved.

PY - 2012

Y1 - 2012

N2 - The four human epidermal growth factor receptors (HER1-4) are involved in growth stimulation and may play a role in endocrine resistance. The receptors form dimers, leading to activation by mutual phosphorylation. Our purpose was to explore the role of the activated receptors (pHER1, pHER2, pHER3) in endocrine treated breast cancer in terms of co-expression and association with disease-free survival (DFS) in 1062 patients with ER-positive tumors. Furthermore, HER2 amplification was evaluated. We found positive associations between the phosphorylated receptors. pHER1 and pHER3 were co-expressed with one or two of the other activated receptors in 85% and 89% of tumors, respectively, whereas pHER2 was co-expressed with the other activated receptors in 54% of tumors. Except for HER2, which was associated with poor prognosis, none of the remaining markers were associated with DFS. However, frequent co-expression indicates a role of the other HER-family members in activation of HER2.

AB - The four human epidermal growth factor receptors (HER1-4) are involved in growth stimulation and may play a role in endocrine resistance. The receptors form dimers, leading to activation by mutual phosphorylation. Our purpose was to explore the role of the activated receptors (pHER1, pHER2, pHER3) in endocrine treated breast cancer in terms of co-expression and association with disease-free survival (DFS) in 1062 patients with ER-positive tumors. Furthermore, HER2 amplification was evaluated. We found positive associations between the phosphorylated receptors. pHER1 and pHER3 were co-expressed with one or two of the other activated receptors in 85% and 89% of tumors, respectively, whereas pHER2 was co-expressed with the other activated receptors in 54% of tumors. Except for HER2, which was associated with poor prognosis, none of the remaining markers were associated with DFS. However, frequent co-expression indicates a role of the other HER-family members in activation of HER2.

KW - Aged

KW - Antineoplastic Agents, Hormonal

KW - Breast Neoplasms

KW - Chemotherapy, Adjuvant

KW - Disease-Free Survival

KW - Double-Blind Method

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Immunohistochemistry

KW - In Situ Hybridization, Fluorescence

KW - Mastectomy

KW - Middle Aged

KW - Nitriles

KW - Phosphorylation

KW - Receptor Protein-Tyrosine Kinases

KW - Receptor, Epidermal Growth Factor

KW - Receptor, erbB-2

KW - Receptor, erbB-3

KW - Tamoxifen

KW - Treatment Outcome

KW - Triazoles

KW - Tumor Markers, Biological

U2 - 10.1016/j.breast.2012.07.005

DO - 10.1016/j.breast.2012.07.005

M3 - Journal article

VL - 21

SP - 662

EP - 668

JO - Breast

JF - Breast

SN - 0960-9776

IS - 5

ER -